{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T14:32:35Z","timestamp":1779114755115,"version":"3.51.4"},"reference-count":43,"publisher":"American Society for Microbiology","issue":"7","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Vaccine Immunol"],"published-print":{"date-parts":[[2013,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Antimicrobials administered postexposure can reduce the incidence or progression of anthrax disease, but they do not protect against the disease resulting from the germination of spores that may remain in the body after cessation of the antimicrobial regimen. Such additional protection may be achieved by postexposure vaccination; however, no anthrax vaccine is licensed for postexposure prophylaxis (PEP). In a rabbit PEP study, animals were subjected to lethal challenge with aerosolized\n            <jats:named-content content-type=\"genus-species\">Bacillus anthracis<\/jats:named-content>\n            spores and then were treated with levofloxacin with or without concomitant intramuscular (i.m.) vaccination with anthrax vaccine adsorbed (AVA) (BioThrax; Emergent BioDefense Operations Lansing LLC, Lansing, MI), administered twice, 1 week apart. A significant increase in survival rates was observed among vaccinated animals compared to those treated with antibiotic alone. In preexposure prophylaxis studies in rabbits and nonhuman primates (NHPs), animals received two i.m. vaccinations 1 month apart and were challenged with aerosolized anthrax spores at day 70. Prechallenge toxin-neutralizing antibody (TNA) titers correlated with animal survival postchallenge and provided the means for deriving an antibody titer associated with a specific probability of survival in animals. In a clinical immunogenicity study, 82% of the subjects met or exceeded the prechallenge TNA value that was associated with a 70% probability of survival in rabbits and 88% probability of survival in NHPs, which was estimated based on the results of animal preexposure prophylaxis studies. The animal data provide initial information on protective antibody levels for anthrax, as well as support previous findings regarding the ability of AVA to provide added protection to\n            <jats:named-content content-type=\"genus-species\">B. anthracis<\/jats:named-content>\n            -infected animals compared to antimicrobial treatment alone.\n          <\/jats:p>","DOI":"10.1128\/cvi.00099-13","type":"journal-article","created":{"date-parts":[[2013,5,9]],"date-time":"2013-05-09T04:01:47Z","timestamp":1368072107000},"page":"1016-1026","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":61,"title":["Evaluation of Immunogenicity and Efficacy of Anthrax Vaccine Adsorbed for Postexposure Prophylaxis"],"prefix":"10.1128","volume":"20","author":[{"given":"Boris","family":"Ionin","sequence":"first","affiliation":[{"name":"Emergent BioSolutions, Gaithersburg, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Hopkins","sequence":"additional","affiliation":[{"name":"Emergent BioSolutions, Gaithersburg, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brett","family":"Pleune","sequence":"additional","affiliation":[{"name":"Emergent BioSolutions, Gaithersburg, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gloria S.","family":"Sivko","sequence":"additional","affiliation":[{"name":"Battelle Memorial Institute, Columbus, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frances M.","family":"Reid","sequence":"additional","affiliation":[{"name":"Battelle Memorial Institute, Columbus, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristin H.","family":"Clement","sequence":"additional","affiliation":[{"name":"Battelle Memorial Institute, Columbus, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"Thomas L.","family":"Rudge","sequence":"additional","affiliation":[{"name":"Battelle Memorial Institute, Columbus, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory V.","family":"Stark","sequence":"additional","affiliation":[{"name":"Battelle Memorial Institute, Columbus, Ohio, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison","family":"Innes","sequence":"additional","affiliation":[{"name":"Emergent BioSolutions, Gaithersburg, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suha","family":"Sari","sequence":"additional","affiliation":[{"name":"Emergent BioSolutions, Gaithersburg, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tina","family":"Guina","sequence":"additional","affiliation":[{"name":"Emergent BioSolutions, Gaithersburg, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cris","family":"Howard","sequence":"additional","affiliation":[{"name":"Emergent BioSolutions, Gaithersburg, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Smith","sequence":"additional","affiliation":[{"name":"Emergent BioSolutions, Gaithersburg, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. Lisa","family":"Swoboda","sequence":"additional","affiliation":[{"name":"Emergent BioSolutions, Gaithersburg, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ekaterina","family":"Vert-Wong","sequence":"additional","affiliation":[{"name":"Emergent BioSolutions, Gaithersburg, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia","family":"Johnson","sequence":"additional","affiliation":[{"name":"Emergent BioSolutions, Gaithersburg, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary S.","family":"Nabors","sequence":"additional","affiliation":[{"name":"Emergent BioSolutions, Gaithersburg, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario H.","family":"Skiadopoulos","sequence":"additional","affiliation":[{"name":"Emergent BioSolutions, Gaithersburg, Maryland, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.287.17.2236"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0041-0101(01)00161-1"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/430843a"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0013888"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(01)00234-1"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.69.5.2888-2893.2001"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0264-410X(01)00197-9"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2003.07.004"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.12.028"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3004073"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0022172400044272"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/167.5.1239"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00090-06"},{"key":"e_1_3_2_15_2","volume-title":"RabAvert rabies vaccine package insert","author":"Novartis Vaccines and Diagnostics","year":"2012","unstructured":"Novartis Vaccines and Diagnostics. 2012. RabAvert rabies vaccine package insert. Novartis Vaccines and Diagnostics, Inc. Cambridge, MA. http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM312931.pdf."},{"key":"e_1_3_2_16_2","volume-title":"Imovax rabies vaccine package insert","author":"Sanofi Pasteur","year":"2012","unstructured":"SanofiPasteur. 2012. Imovax rabies vaccine package insert. Sanofi Pasteur, Inc. Swiftwater, PA. http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM133484.pdf."},{"key":"e_1_3_2_17_2","volume-title":"ENGERIX-B hepatitis B vaccine (recombinant) package insert","author":"GlaxoSmithKline","year":"2012","unstructured":"GlaxoSmithKline. 2012. ENGERIX-B hepatitis B vaccine (recombinant) package insert. GlaxoSmithKline, Rixensart, Belgium. http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM224503.pdf."},{"key":"e_1_3_2_18_2","unstructured":"Merck & Co. 2011. RECOMBIVAX HB\u00ae hepatitis B vaccine (recombinant) package insert. Merck & Co. Inc. Whitehouse Station NJ. http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM110114.pdf."},{"key":"e_1_3_2_19_2","volume-title":"Tetanus toxoid adsorbed package insert","author":"Aventis Pasteur","year":"2005","unstructured":"AventisPasteur. 2005. Tetanus toxoid adsorbed package insert. Aventis Pasteur, Swiftwater, PA. http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/Vaccines\/ApprovedProducts\/UCM142732.pdf."},{"key":"e_1_3_2_20_2","volume-title":"BioThrax (anthrax vaccine adsorbed) package insert","author":"Emergent BioSolutions","year":"2012","unstructured":"EmergentBioSolutions. 2012. BioThrax (anthrax vaccine adsorbed) package insert. Emergent BioDefense Operations Lansing LLC, Lansing, MI. http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/BloodBloodProducts\/ApprovedProducts\/LicensedProductsBLAs\/UCM074923.pdf."},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.52.4.632"},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.21236\/ADA403352"},{"key":"e_1_3_2_23_2","volume-title":"Title 21. Food and drugs. Chapter I. Food and Drug Administration. Subchapter F. Biologics. Part 601. Review procedures to determine that licensed biological products are safe, effective, and not misbranded under prescribed, recommended, or suggested conditions of use. 21 CFR 601.25","author":"Code of Federal Regulations","year":"2012","unstructured":"Code of Federal Regulations. 2012. Title 21. Food and drugs. Chapter I. Food and Drug Administration. Subchapter F. Biologics. Part 601. Review procedures to determine that licensed biological products are safe, effective, and not misbranded under prescribed, recommended, or suggested conditions of use. 21 CFR 601.25. http:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/CFRSearch.cfm?fr=601.25."},{"key":"e_1_3_2_24_2","volume-title":"Title 21. Food and drugs. Chapter I. Food and Drug Administration. Subchapter F. Biologics. Part 601. Approval based on a surrogate endpoint or on an effect on a clinical endpoint other than survival or irreversible morbidity. 21 CFR 601.41","author":"Code of Federal Regulations","year":"2012","unstructured":"Code of Federal Regulations. 2012. Title 21. Food and drugs. Chapter I. Food and Drug Administration. Subchapter F. Biologics. Part 601. Approval based on a surrogate endpoint or on an effect on a clinical endpoint other than survival or irreversible morbidity. 21 CFR 601.41. http:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/CFRSearch.cfm?fr=601.41."},{"key":"e_1_3_2_25_2","volume-title":"Guidance for industry: clinical data needed to support the licensure of seasonal inactivated influenza vaccines. U.S. Department of Health and Human Services. Food and Drug Administration","author":"FDA","year":"2007","unstructured":"FDA. 2007. Guidance for industry: clinical data needed to support the licensure of seasonal inactivated influenza vaccines. U.S. Department of Health and Human Services. Food and Drug Administration. http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/GuidanceComplianceRegulatoryInformation\/Guidances\/Vaccines\/ucm091990.pdf."},{"key":"e_1_3_2_26_2","volume-title":"Transcript of Vaccines and Related Biological Products Advisory Committee Meeting","author":"Vaccines and Related Biological Products Advisory Committee","year":"2007","unstructured":"Vaccines and Related Biological Products Advisory Committee. 17 May 2007. Transcript of Vaccines and Related Biological Products Advisory Committee Meeting. U.S. Department of Health and Human Services, Food and Drug Administration. Gaithersburg, MD. http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/07\/transcripts\/2007-4292t2.pdf."},{"key":"e_1_3_2_27_2","volume-title":"Vaccines and Related Biological Products Advisory Committee meeting summary minutes. U.S. Department of Health and Human Services, Food and Drug Administration","author":"Vaccines and Related Biological Products Advisory Committee","year":"2011","unstructured":"Vaccines and Related Biological Products Advisory Committee. 6\u20137 April 2011. Vaccines and Related Biological Products Advisory Committee meeting summary minutes. U.S. Department of Health and Human Services, Food and Drug Administration. http:\/\/www.fda.gov\/AdvisoryCommittees\/CommitteesMeetingMaterials\/BloodVaccinesandOtherBiologics\/VaccinesandRelatedBiologicalProductsAdvisoryCommittee\/ucm254361.htm."},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.coviro.2012.01.004"},{"key":"e_1_3_2_29_2","volume-title":"Guidance for industry animal models: essential elements to address efficacy under the Animal Rule. U.S. Department of Health and Human Services, Food and Drug Administration","author":"CDER and CBER","year":"2009","unstructured":"CDER and CBER. 2009. Guidance for industry animal models: essential elements to address efficacy under the Animal Rule. U.S. Department of Health and Human Services, Food and Drug Administration. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm078923.pdf."},{"key":"e_1_3_2_30_2","author":"CBER","year":"2007","unstructured":"CBER. 8 November 2007. Anthrax vaccines: bridging correlates of protection in animals to immunogenicity in humans. U.S. Department of Health and Human Services, Food and Drug Administration. http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/NewsEvents\/WorkshopsMeetingsConferences\/TranscriptsMinutes\/UCM054424.pdf.","journal-title":"Anthrax vaccines: bridging correlates of protection in animals to immunogenicity in humans. U.S. Department of Health and Human Services, Food and Drug Administration"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1086\/596063"},{"key":"e_1_3_2_32_2","volume-title":"Anthrax vaccines: efficacy testing and surrogate markers of immunity. U.S. Department of Health and Human Services, Food and Drug Administration","author":"CBER","year":"2002","unstructured":"CBER. 23 April 2002. Anthrax vaccines: efficacy testing and surrogate markers of immunity. U.S. Department of Health and Human Services, Food and Drug Administration. http:\/\/www.fda.gov\/downloads\/BiologicsBloodVaccines\/NewsEvents\/WorkshopsMeetingsConferences\/TranscriptsMinutes\/UCM054606.pdf."},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00240-12"},{"key":"e_1_3_2_34_2","unstructured":"Vaccines and Related Biological Products Advisory Committee. 16 November 2010. Transcript of FDA Advisory Committee Meeting. Vaccines and Related Biological Products Advisory Committee Meeting Materials. U.S. Department of Health and Human Services Food and Drug Administration. http:\/\/www.fda.gov\/AdvisoryCommittees\/CommitteesMeetingMaterials\/BloodVaccinesandOtherBiologics\/VaccinesandRelatedBiologicalProductsAdvisoryCommittee\/ucm237045.htm."},{"key":"e_1_3_2_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/B978-1-4160-3611-1.50012-X"},{"key":"e_1_3_2_36_2","first-page":"982","article-title":"The pathology of experimental anthrax in rabbits exposed by inhalation and subcutaneous inoculation","volume":"122","author":"Zaucha GM","year":"1998","unstructured":"ZauchaGM PittLM EstepJ IvinsBE FriedlanderAM. 1998. The pathology of experimental anthrax in rabbits exposed by inhalation and subcutaneous inoculation. Arch. Pathol. Lab. Med. 122:982\u2013992.","journal-title":"Arch. Pathol. Lab. Med."},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.LAB.0000080599.43791.01"},{"key":"e_1_3_2_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2008.01.007"},{"key":"e_1_3_2_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00003-08"},{"key":"e_1_3_2_40_2","doi-asserted-by":"publisher","DOI":"10.3201\/eid0810.020380"},{"key":"e_1_3_2_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00324-12"},{"key":"e_1_3_2_42_2","volume-title":"Bacillus-ACT 2009: the International Bacillus anthracis, B. cereus, and B. thuringiensis Conference","author":"Chakrabarti A","year":"2009","unstructured":"ChakrabartiA HopkinsR MalkevichN IoninB SkiadopoulosM SmithJ NaborsG. 2009. Recent advances in the development of a human anthrax intravenous immune globulin (AIGIV) for treatment of inhalation anthrax disease, abstr. 119C. Bacillus-ACT 2009: the International Bacillus anthracis, B. cereus, and B. thuringiensis Conference, Santa Fe, NM."},{"key":"e_1_3_2_43_2","volume-title":"Bacillus-ACT 2011: the International Bacillus anthracis, B. cereus, and B. thuringiensis Conference","author":"Basu S","year":"2011","unstructured":"BasuS MytleN Van ZandtKE MeisterGT IoninB ChakrabartiAC NaborsGS SkiadopoulosMH. 2011. Postexposure efficacy of human anthrax immune globulin, intravenous (AIGIV) in rabbits, abstr. 119-Mo. Bacillus-ACT 2011: the International Bacillus anthracis, B. cereus, and B. thuringiensis Conference, Bruges, Belgium."},{"key":"e_1_3_2_44_2","unstructured":"NuzumE. 16 November 2010. DMID\/NIAID efforts that support the pathway to licensure for protective antigen-based anthrax vaccines for a post-exposure indication using the animal rule. Vaccines and Related Biological Products Advisory Committee Meeting Presentations (PPTX-895KB). http:\/\/www.fda.gov\/AdvisoryCommittees\/CommitteesMeetingMaterials\/BloodVaccinesandOtherBiologics\/VaccinesandRelatedBiologicalProductsAdvisoryCommittee\/ucm239733.htm."}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00099-13","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00099-13","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T20:49:15Z","timestamp":1627591755000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00099-13"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["10.1128\/CVI.00099-13"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00099-13","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7]]},"assertion":[{"value":"2013-02-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-04-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-06-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}